Clinicians treating atrial fibrillation must initially identify and ultimately verify whether this
rhythm fits within the definition of “non-valvular” atrial fibrillation (NVAF). The spectrum of …

The term non-valvular atrial fibrillation (NVAF) has become popular with the development of
non-vitamin K antagonists (VKA) novel oral anticoagulants (NOAC), or direct oral …

Non-vitamin K antagonist oral anticoagulants (NOACs) are approved for prevention of stroke
in patients with non-valvular atrial fibrillation (NVAF). These agents are as effective as …

As a progressive atrial myopathy, the etiopathogenesis of AF is multifactorial. For example,
valvular heart disease are found in 30% of AF patients and in mitral stenosis and/or …

Non-vitamin K oral anticoagulants (NOACs) have become the standard of care for stroke
prevention in patients with non-valvular atrial fibrillation (AF), based on the impressive …

Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials comparing vitamin K
antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in AF were …

We have greatly enjoyed reading the recently published article by Noseworthy et al. entitled
“Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants …

Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia, and is associated
with an increased risk of death, stroke, and other thromboembolic events. Valvular heart …

Non–vitamin K oral anticoagulants (NOACs) are currently recommended for patients with
nonvalvular atrial fibrillation since the publication of the 4 major pivotal trials evaluating the …

Aims To evaluate the potential impact of the different definitions of non-valvular atrial
fibrillation reported in the literature and to analyse the possible implications for eligibility for …